Article
Cell Biology
Jia Xia, Jiahui Zhang, Liangzhe Wang, Hailong Liu, Jie Wang, Junyan Liu, Zhaoqian Liu, Yingjian Zhu, Yingjie Xu, Wen Yang, Yongjiang Yu
Summary: Caspase-8 plays a dual role in cell death and survival in cancer, and its upregulation in enzalutamide-resistant prostate cancer leads to increased NF-kappa B/IL-8 mediated survival signaling, contributing to therapy resistance. Targeting Caspase-8 and NF-kappa B may be a potential strategy to overcome enzalutamide resistance in CRPC.
CELL DEATH & DISEASE
(2021)
Article
Pharmacology & Pharmacy
Erika Powe, Daniel Parschauer, Jessica Istifan, Stacy Lin, Huanyun Duan, Rebecca Gryka, Denise Jean-Louis, Amit K. K. Tiwari, Samson Amos
Summary: The overexpression of EGFR in glioblastoma leads to increased tumor cell proliferation, decreased apoptosis, and resistance to chemotherapy. The combination of erlotinib and luteolin inhibits cell proliferation and induces apoptosis in glioblastoma cells with EGFR mutations or expression. Additionally, this combination reduces the phosphorylation of downstream signaling molecules. This suggests that combining erlotinib with luteolin may be an effective treatment strategy for glioblastoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Ke Gao, Xiaoshun Li, Jianxin Ni, Bin Wu, Jiaheng Guo, Rui Zhang, Guojun Wu
Summary: This article introduces the roles of dysregulation of different subclasses of non-coding RNAs (ncRNAs) in the development of castration-resistant prostate cancer (CRPC) progression and Enzalutamide (Enz) resistance. The mechanisms of Enz resistance, including AR-splice variant-7 (AR-V7), mutations, circRNAs, and lncRNAs that act as miRNA sponges, are discussed. The contributions of epithelial-mesenchymal transition and glucose metabolism to Enz resistance are also highlighted. The article summarizes the different mechanisms of miRNAs, lncRNAs, and circRNAs in the progression of CRPC and Enz resistance, and discusses future therapeutic strategies against Enz resistance.
Article
Medicine, Research & Experimental
Phung Nguyen, Phuong Doan, Akshaya Murugesan, Thiyagarajan Ramesh, Tatu Rimpilainen, Nuno R. Candeias, Olli Yli-Harja, Meenakshisundaram Kandhavelu
Summary: The study demonstrates that CHBC induces G2/M cell cycle arrest and apoptosis by disrupting MAPK signaling in human glioblastoma cells. CHBC could potentially be a class of compounds for treating glioblastoma.
Review
Biochemistry & Molecular Biology
Maya A. Dymova, Elena Kuligina, Vladimir A. Richter
Summary: This review summarizes recent advances in understanding the molecular mechanisms of therapeutic resistance of GBM, molecular characteristics of glioblastoma cells, and barriers in the brain that contribute to drug resistance. The progress in developing new targeted drugs for glioblastoma and drug delivery across the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) is also discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Jr-Di Yang, Jui-Tai Chen, Shing-Hwa Liu, Ruei-Ming Chen
Summary: The testosterone androgen receptor (AR)-PARD3B signaling axis plays an important role in the tumorigenesis and malignancy of human glioblastoma multiforme (GBM) by stimulating cell proliferation and colony formation. The study found that AR and PARD3B gene expressions were upregulated in GBM tissues, and there was a strong positive correlation between their expressions.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Bingke Bai, Qianbo Chen, Rui Jing, Xuhui He, Hongrui Wang, Yanfei Ban, Qi Ye, Weiheng Xu, Chengjian Zheng
Summary: Prostate cancer is the second most common malignant cancer in males, and the cure remains challenging. Natural compounds have the potential to provide chemical agents for treatment. While natural products are becoming ideal choices for prostate cancer treatment, further research is still needed.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yara Rodriguez, Kenji Unno, Mihai I. Truica, Zachary R. Chalmers, Young A. Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain, Huiying Han, Sarki A. Abdulkadir
Summary: This study identifies PRRX2 as a driver of enzalutamide resistance in prostate cancer. PRRX2 expression is highest in double-negative prostate cancer cases and its associated gene signature can serve as a biomarker for enzalutamide resistance, which can be reversed with CDK4/6 and BCL2 inhibitors.
Article
Oncology
Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Summary: AMG 160, a bispecific T-cell engager immuno-oncology therapy targeting PSMA in mCRPC, demonstrates potent antitumor activity in vitro and in vivo. It shows enhanced cytotoxic activity when combined with diagnostic or therapeutic agents such as the PSMA-imaging agent, novel hormonal therapy, and immune checkpoint blockade. Preclinical data supports ongoing clinical evaluation in patients with mCRPC.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow, Suresh K. Alahari
Summary: Combination therapy with ceritinib and enzalutamide inhibits the growth of AR(+) TNBC cells, while combination therapy with ceritinib and paclitaxel drastically inhibits tumor growth. These findings suggest that combination treatment with these FDA-approved drugs can improve the therapeutic response in both AR-positive and negative breast cancer.
Article
Materials Science, Biomaterials
Ze Gao, Jun Huang, Zhaoxiang Xie, Peikun Xin, Hao Huang, Tao Du, Jun Wu, Hai Huang
Summary: This article proposes a strategy of using a biocompatible nanoparticle drug delivery system to improve the bioavailability and therapeutic performance of enzalutamide. The system has been shown to enhance drug delivery efficiency, increase drug cytotoxicity, and reduce the half-inhibitory concentration of the drug, thus demonstrating great potential for the treatment of prostate cancer.
BIOMATERIALS SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Manuel Morales, Pablo Martin-Vasallo, Julio Avila
Summary: Enzalutamide treatment may increase the risk of cardiovascular-related hospitalization in patients, potentially due to MR gene polymorphism, suggesting the importance of evaluating MR rs5522 polymorphism before starting AR inhibitor therapy.
Article
Nanoscience & Nanotechnology
Vijaya Sarangthem, Aena Yi, Yunjae Kim, Alnawaz Rehemtulla, Byung-Heon Lee, Young Hyun Jeon, Thoudam Debraj Singh, Rang-Woon Park
Summary: The study demonstrated that AP1-ELP-KLAK effectively induced cellular apoptosis in glioblastoma cells with high expression of IL-4R. Real-time monitoring of therapeutic effect using BLI technology showed that AP1-ELP-KLAK reduced tumor growth and induced cellular apoptosis.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Longjun Ma, Yan Zhou, Dehua Yang, Ming-Wei Wang, Wei Lu, Jiyu Jin
Summary: Hydroxymethylthiohydantoin, hydroxymethylthiohydantoin, and hydantoin, all containing a pyridine group, were synthesized to investigate their androgen receptor antagonistic activities. Among them, compounds 6a/6c/7g/19a/19b showed remarkable antagonistic activity against the androgen receptor, comparable to or even surpassing enzalutamide. Additionally, compounds 19a and 19b exhibited superior antiproliferative activity compared to enzalutamide in prostate cancer cells. These findings suggest that compound 19a holds promising potential as a novel AR antagonist.
Article
Biochemistry & Molecular Biology
Eliot B. Blatt, Karla Parra, Antje Neeb, Lorenzo Buroni, Denisa Bogdan, Wei Yuan, Yunpeng Gao, Collin Gilbreath, Alec Paschalis, Suzanne Carreira, Ralph J. DeBerardinis, Ram S. Mani, Johann S. de Bono, Ganesh V. Raj
Summary: Therapy resistance to enzalutamide, a second-generation androgen receptor antagonist, is common in advanced prostate cancer (PCa) patients. This resistance is associated with higher levels of reactive oxygen species (ROS) and enhanced glutamine metabolism. Inhibiting glutamine metabolism or targeting antioxidant pathways can block the growth of enzalutamide-resistant PCa cells.
Article
Clinical Neurology
Hsiao-Chien Tsai, Ta-Liang Chen, Yu-Pin Chen, Ruei-Ming Chen
JOURNAL OF PAIN RESEARCH
(2018)
Article
Oncology
Chung-Ching Chio, Kung-Yen Chen, Cheng-Kuei Chang, Jian-Ying Chuang, Chih-Chung Liu, Shing-Hwa Liu, Ruei-Ming Chen
Article
Environmental Sciences
Jr-Di Yang, Shing-Hwa Liu, Mei-Hsiu Liao, Ruei-Ming Chen, Pei-Yu Liu, Tzuu-Huei Ueng
ENVIRONMENTAL TOXICOLOGY
(2018)
Article
Plant Sciences
Chung-Ching Chio, Yu-Ting Tai, Mahendravarman Mohanraj, Shing-Hwa Liu, Shun-Tai Yang, Ruei-Ming Chen
Article
Multidisciplinary Sciences
Poh-Shiow Yeh, Yuan-Wen Lee, Wei-Hui Chang, Weu Wang, Jaw-Lin Wang, Shing-Hwa Liu, Ruei-Ming Chen
Review
Biochemistry & Molecular Biology
Yi-Chou Hou, Chien-Lin Lu, Cai-Mei Zheng, Wen-Chih Liu, Tzung-Hai Yen, Ruei-Ming Chen, Yuh-Feng Lin, Chia-Ter Chao, Kuo-Cheng Lu
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Biochemistry & Molecular Biology
Gong-Jhe Wu, Sun-Ta Yang, Ruei-Ming Chen
Article
Biochemistry & Molecular Biology
Poh-Shiow Yeh, Jui-Tai Chen, Yih-Giun Cherng, Shun-Tai Yang, Yu-Ting Tai, Ruei-Ming Chen
Article
Agriculture, Multidisciplinary
Gong-Jhe Wu, Jui-Tai Chen, Yih-Giun Cherng, Chuen-Chau Chang, Shing-Hwa Liu, Ruei-Ming Chen
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2020)
Article
Cell Biology
Yuan-Wen Lee, Yih-Giun Cherng, Shun-Tai Yang, Shing-Hwa Liu, Ta-Liang Chen, Ruei-Ming Chen
Summary: The study demonstrated that long-term treatment with CoCl2 induces hypoxia and subsequent autophagic apoptosis in drug-resistant glioblastoma cells by targeting the PI3K-AKT-mTOR pathway. Subsequent apoptotic insults lead to cell death.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2021)
Article
Agriculture, Multidisciplinary
Gong-Jhe Wu, Kung-Yen Chen, Jr-Di Yang, Shing-Hwa Liu, Ruei-Ming Chen
Summary: The study showed that naringin, a citrus flavonoid, can enhance bone mineralization and healing in osteoporosis-related bone diseases by activating ERα and ALP expression.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2021)
Article
Medicine, General & Internal
Jr-Di Yang, Jui-Tai Chen, Shing-Hwa Liu, Ruei-Ming Chen
Summary: The testosterone androgen receptor (AR)-PARD3B signaling axis plays an important role in the tumorigenesis and malignancy of human glioblastoma multiforme (GBM) by stimulating cell proliferation and colony formation. The study found that AR and PARD3B gene expressions were upregulated in GBM tissues, and there was a strong positive correlation between their expressions.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Chien-Chou Lin, Li-Hsuan Chiu, Walter H. H. Chang, Cheng-An J. Lin, Ruei-Ming Chen, Yuan-Soon Ho, Chun S. S. Zuo, Austin Changou, Yue-Fa Cheng, Wen-Fu T. Lai
Summary: Computed tomography and conventional X-ray radiography often create micro-artifacts around metal implants, leading to false diagnoses of bone maturation or pathological peri-implantitis. A novel NIRF molecular imaging system was developed to repair these artifacts and monitor bone maturation. The system accurately identified image loss caused by metal artifacts and can be used to evaluate new types of implant fixtures or surface treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Ding-Ping Sun, Jui-Tai Chen, Shun-Tai Yang, Tso-Hsiao Chen, Shing-Hwa Liu, Ruei-Ming Chen
Summary: This study investigated the effect of resveratrol on neuroblastoma cells and the survival of mice with neuroblastomas. Resveratrol induced apoptosis and autophagy in neuroblastoma cells and triggered ER stress and iROS production. It also suppressed cell migration by inhibiting the ER stress-iROS axis. Resveratrol had minimal side effects and extended the survival of neuroblastoma-bearing mice. This research suggests that resveratrol could be a potential drug candidate for neuroblastoma chemotherapy.
CHEMICO-BIOLOGICAL INTERACTIONS
(2023)